Claim: CD163 shedding occurs as a result of enzymatic cleavage by ADAM17, and it is upregulated in a large range of inflammatory diseases including liver cirrhosis,  which develops slowly and is often no symptoms.
Evidence: A soluble form of the receptor exists in plasma, and cerebrospinal fluid., commonly denoted sCD163. sCD163 shedding occurs as a result of enzymatic cleavage by ADAM17. sCD163 is upregulated in a large range of inflammatory diseases including liver cirrhosis, type 2 diabetes, macrophage activation syndrome, Gaucher's disease, sepsis, HIV infection, rheumatoid arthritis and Hodgkin Lymphoma. Typically, the disease develops slowly over months or years. Early on, there are often no symptoms.